PMV Pharmaceuticals, Inc. (PMVP)
- Previous Close
0.9500 - Open
0.9586 - Bid 0.9226 x 100
- Ask 1.0200 x 100
- Day's Range
0.9401 - 0.9885 - 52 Week Range
0.8100 - 1.8300 - Volume
798,949 - Avg. Volume
192,612 - Market Cap (intraday)
50.394M - Beta (5Y Monthly) 1.43
- PE Ratio (TTM)
-- - EPS (TTM)
-1.1800 - Earnings Date Aug 6, 2025 - Aug 11, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.67
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is based in Princeton, New Jersey.
www.pmvpharma.comRecent News: PMVP
View MorePerformance Overview: PMVP
Trailing total returns as of 6/6/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PMVP
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PMVP
View MoreValuation Measures
Market Cap
50.39M
Enterprise Value
-108.89M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.31
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-27.24%
Return on Equity (ttm)
-32.66%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-60.88M
Diluted EPS (ttm)
-1.1800
Balance Sheet and Cash Flow
Total Cash (mrq)
160.39M
Total Debt/Equity (mrq)
0.69%
Levered Free Cash Flow (ttm)
-47.35M